Core Viewpoint - The company has shown improvement in financial performance, expanding its business scale, deepening the application of digital platforms, and experiencing a clear trend of industry concentration, attracting institutional attention [1]. Financial Performance - For the first three quarters of 2025, the company reported revenue of 609 million, a year-on-year increase of 2.59%, and a net profit attributable to shareholders of 87.38 million, up 20.92%. In the third quarter alone, revenue reached 219 million, reflecting a year-on-year growth of 9.84%, while net profit surged by 91.6% to 33.23 million, with a gross margin increase to 25.58% [2]. Business Development - As of the end of September 2025, the company has undertaken over 4,200 international and domestic SMO projects, with 2,538 projects currently in execution. The service scope includes the top ten global pharmaceutical companies in 2024, such as Merck and AstraZeneca, indicating a quarterly growth trend in project numbers and demonstrating business resilience [3]. Technological Advancements - The company has developed its own platform, the "Rui Xing" intelligent management system, which integrates AI functionalities to enhance the efficiency of clinical trials. Investor relations activities in 2025 indicated that this platform has achieved data visualization and intelligent management, contributing to improved service quality [4]. Industry Environment - According to investor activities in February 2026, resources in the SMO industry are gradually concentrating towards leading enterprises. As a leading company, the firm benefits from regulatory policy support and accumulated customer resources, optimizing the competitive landscape of the industry [5]. Institutional Interest - In January 2026, the company hosted discussions with several institutions, including Huatai PineBridge Fund, focusing on business strategy and quality management systems. Over the past year, the company has received a total of 210 institutional visits, reflecting a high level of market interest [6].

Core Viewpoint - The recent round of national drug procurement has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas, with only 21 original drugs selected, representing less than 10% of the total [1][2]. Group 1: Procurement Details - The procurement aims to reduce drug prices and patient burdens while reallocating saved healthcare funds to innovative drugs [2]. - The procurement process involved 51,000 medical institutions, with a high selection rate of 93% and an average of 14 companies selected per product [2][3]. - The results of this procurement are expected to be implemented by the end of March 2026, with a procurement cycle lasting until the end of 2028 [2]. Group 2: Original Drug Participation - The selected original drugs include various formulations from companies like Bristol-Myers Squibb, Sanofi, and Bayer, with some previously shortlisted in earlier rounds [3]. - Notable original drugs that did not participate in this round include AstraZeneca's gefitinib and Sanofi's clopidogrel, which had previously been selected [4][3]. Group 3: Market Dynamics - The phenomenon known as "patent cliff" has led to significant declines in sales and profits for original drugs post-patent expiration, making it challenging for them to maintain market share without substantial price reductions [6]. - Some original drug companies have reduced or dissolved their sales teams for products affected by procurement policies, yet many still find market opportunities outside public hospital procurement [7]. - Cross-national pharmaceutical companies are increasingly focusing on innovative drug development while divesting mature product lines to local firms [8][9].

2026.02. 12 本文字数：2499，阅读时长大约4分钟 作者 | 第一财经 林志吟 近日，1至8批国家集采药品新一轮接续采购已诞生拟中选结果，共有1020家企业的4163个产品获 得拟中选资格，涉及316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、 呼吸系统、消化系统等26个治疗领域。 从这接续采购的316种药品来看，据第一财经记者统计，有原研药中标的品种共有21个，整体占比 不到一成。 不到一成的原研药中标 国家药品集采，针对的仿制药以及过了专利保护期的原研药这两大类产品，一方面，挤掉药价虚高的 水分，降低患者用药负担；另外一方面，通过集采节省下的医保资金，转向支付临床价值显著的创新 药，满足临床亟需，鼓励药企研发创新。 本次是针对1-8批国家集采药品新一轮接续采购，由江苏、河南、广东三省医保局联合牵头，各省份 全部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销售。具备投标资 格的企业绝大多数参与投标报价，整体中选率高达93%，每个品种平均14家企业中选。 本次接续采购，国内药品上市许可持有人（含药品注册批件持有人）、境外药品上市许可持有人及其 境内责任 ...

凭借品牌优势在院外市场找到新的发展空间。 近日，1至8批国家集采药品新一轮接续采购已诞生拟中选结果，共有1020家企业的4163个产品获得拟中 选资格，涉及316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系 统、消化系统等26个治疗领域。 2018年以来，随着国家组织的药品集采启动，医药行业逐渐走向分水岭，过了专利保护期的原研药难以 在中国市场维持高利润且垄断局面，而原来以销售这类药物为生的跨国药企这几年已在密集调整业务， 重塑在华发展战略。 一些原研药虽然缺席集采，但并不意味着从市场消失，相反凭借品牌优势仍在院外市场找到新的发展空 间。 不到一成的原研药中标 国家药品集采，针对的仿制药以及过了专利保护期的原研药这两大类产品，一方面，挤掉药价虚高的水 分，降低患者用药负担；另外一方面，通过集采节省下的医保资金，转向支付临床价值显著的创新药， 满足临床亟需，鼓励药企研发创新。 本次是针对1-8批国家集采药品新一轮接续采购，由江苏、河南、广东三省医保局联合牵头，各省份全 部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销售。具备投标资格的 企业绝大多数参与投标报价 ...

Core Insights - The medical sector is experiencing both "explosive growth" and "cooling" simultaneously, with over 100 medical companies queued for IPOs in Hong Kong, and tightening IPO policies expected [1][3] - The performance of new drug IPOs in 2026 is anticipated to be significantly differentiated, with many companies initiating Pre-IPO financing to hedge against regulatory tightening and market risks [4][5] Group 1: IPO Trends and Market Dynamics - The number of companies waiting for IPOs in Hong Kong has exceeded 400, indicating a crowded market, and the performance of these IPOs is likely to vary widely [4] - Investors are expected to favor companies with successful overseas BD (business development) cases and clear product timelines, while those lacking competitive advantages may face significant IPO pressure [4] - The market sentiment is cautious, with many companies considering Crossover financing to mitigate risks associated with the tightening IPO window [5] Group 2: BD Transactions and Investment Opportunities - The enthusiasm for BD transactions from multinational corporations (MNCs) towards Chinese new drug assets remains high, with China accounting for 50% of global BD transaction volume last year [9][8] - The valuation of Chinese new drugs is expected to stabilize, but there are concerns about rising prices that could harm the reputation of Chinese biotech in the global market [9][8] - The focus of BD transactions is shifting from oncology to other therapeutic areas such as autoimmune and cardiovascular diseases, indicating a diversification of investment interests [12] Group 3: AI in Pharmaceuticals and Medical Devices - AI-driven pharmaceutical companies are gaining traction, with significant funding and BD opportunities expected in 2026, emphasizing the importance of data in drug development [15][16] - The AI revolution is anticipated to first impact consumer medical devices, with AI enhancing product effectiveness and consumer willingness to invest in advanced home healthcare devices [17][18] - The competitive landscape for AI in healthcare is evolving, with a focus on developing tools that can integrate various data types to assist clinical decision-making [19][20] Group 4: Medical Device Market Outlook - The investment landscape for innovative medical devices is currently low but is expected to gradually improve, with structural investment opportunities emerging [26][28] - The challenges of international expansion for Chinese medical devices are significant, but improvements in product quality and performance are paving the way for better market acceptance [31][32] - The future of medical device exports is shifting towards local production and direct sales networks, enhancing profitability and market penetration [32][33]

Market Performance - Kolunbotai Biotech-B (06990.HK) experienced a decline of 3.33% on February 12, 2026, closing at HKD 423.40 with a trading volume of HKD 208 million, influenced by a general market downturn [1] - The Hang Seng Index fell by 0.86%, and the Hang Seng Tech Index dropped by 1.65%, with the biotechnology sector down by 0.84%, reflecting a decrease in market risk appetite affecting high-valuation biotech stocks [1] Institutional Insights - Bank of America Securities raised the target price for the company from HKD 470 to HKD 479 but maintained a "Neutral" rating, adjusting the annual treatment cost assumption for Sac-TMT (Lukangshatu Zhunzai) downwards, leading to a 5% and 6% reduction in revenue forecasts for 2026 and 2027 respectively, which may raise concerns about the product's commercialization profitability [2] Financial and Technical Analysis - Technical indicators show weakness, with the stock price falling below the 5-day moving average of HKD 428.2, and the MACD divergence value at -2.862, indicating insufficient bullish momentum [3] - There was a net outflow of HKD 11.09 million from major funds, while retail investors saw a net inflow of HKD 1.96 million, suggesting a cautious attitude from larger investors [3] Company Valuation - The company's price-to-earnings ratio (TTM) stands at -124.68, and the price-to-book ratio is 17.96, significantly higher than traditional pharmaceutical companies [4] - Despite the approval of the fourth indication for Sac-TMT (HR+/HER2- breast cancer) and its inclusion in the medical insurance list, increased competition in the TROP2 ADC space (e.g., AstraZeneca/Daiichi Sankyo's Enhertu) raises concerns about its long-term pricing advantage [4] Recent Company Status - CICC maintains an "Outperform" rating with a target price of HKD 550, but key catalysts for 2026, such as the FDA application for Sac-TMT and new clinical data, have yet to materialize, resulting in a lack of significant positive drivers for the stock price in the short term [5]

智通财经APP获悉，赛诺菲(SNY.US)于2月12日突然宣布首席执行官Paul Hudson下课，由默沙东 (MRK.US)集团高管贝伦·加里霍接任。这家法国制药巨头此前大幅加码研发投入，却迟迟未见成果，董 事会的耐心已然耗尽。截至发稿，该股盘前跌超6%。 Paul Hudson执掌赛诺菲六年有余，任内一直试图为重磅药物Dupixent寻找"接棒者"——这款哮喘及特应 性皮炎药物正面临专利悬崖，销售峰值过后收入将急转直下。然而关键布局屡屡落空：去年三项后期临 床实验结果混杂乃至失败，令股东失望情绪集中爆发。 "如果2020年你问我，赛诺菲需要五到七年吗?当时我斩钉截铁说不会。"Paul Hudson今年1月底在业绩会 上坦言，"我们更聪明、更强，一定能更快——可惜事与愿违。" 去年赛诺菲出清消费者健康业务控股权，意味着公司未来将完全依赖创新处方药。分析师约翰·墨菲、 米拉·班科夫斯卡娅评价称，Paul Hudson大幅重塑了这家曾被诟病"法式保守"的企业文化，提升其全球 站位，并规划出至2030年的盈利增长路径。然而，由于未能攻克研发效率痼疾、也未能为Dupixent找到 真正继任者，赛诺菲估值倍数始终跑输 ...

Core Viewpoint - The medical sector is experiencing both "explosive growth" and "cooling" simultaneously, with over 100 medical companies queued for IPOs in Hong Kong, while tightening IPO policies are anticipated [4][5]. Group 1: IPO Trends and Market Dynamics - The performance of new drug IPOs in 2026 is expected to be significantly differentiated, with over 400 companies currently in the queue for IPOs in Hong Kong [8]. - Investors are becoming more mature and demanding higher standards for IPO projects, focusing on companies with successful overseas BD cases and clear product sales expectations [8][9]. - Many companies are considering Pre-IPO financing to hedge against tightening regulations and market risks, with valuations typically in the range of $300 million to $500 million [9][10]. Group 2: BD Transactions and Market Sentiment - The enthusiasm for BD transactions from multinational corporations (MNCs) towards Chinese new drug assets remains high, with China accounting for 50% of global BD transaction volume last year [12]. - However, the perception of Chinese new drugs as "value for money" is diminishing, leading to a potential slowdown in the growth rate of BD transactions [12][13]. - The focus of BD transactions is shifting from oncology to autoimmune and cardiovascular treatments, with a growing interest in complementary pipelines [14][15]. Group 3: AI in Drug Development and Healthcare - AI-driven pharmaceutical companies are gaining traction, with significant funding and BD opportunities expected in 2026, although the market is becoming increasingly competitive [20][21]. - The application of AI in consumer medical devices and digital therapies is anticipated to unlock new opportunities, particularly in home healthcare products [23][24]. - AI's role in enhancing clinical decision-making and patient management is expected to revolutionize healthcare delivery, making medical information more accessible [24][25]. Group 4: Medical Device Market Outlook - The investment landscape for innovative medical devices is currently at a low point but is expected to gradually improve, with structural investment opportunities emerging [33][34]. - The challenges of international expansion for medical devices are greater than for new drugs, but there are signs of improvement as leading Chinese manufacturers enhance their product capabilities [37][38]. - The future of medical device exports is shifting towards local production and direct sales networks, moving away from simple product exports [38][39].

Core Viewpoint - The recent announcement by Shenzhen Kangtai Biological Products Co., Ltd. regarding the termination of the concerted action agreement between its actual controllers, Du Weimin and Yuan Liping, has reignited concerns over the company's control stability and potential shareholder dilution following their high-profile divorce that split a market value of 23.5 billion yuan [3][5]. Group 1: Shareholder Dynamics - The termination of the concerted action agreement has resulted in Du Weimin's voting rights decreasing from 46.62% to 25.50%, while Yuan Liping now holds 17.07% [5]. - Yuan Liping has committed not to seek control of the company post-termination, aiming to alleviate market concerns regarding control instability [5]. - Since the divorce in 2020, Yuan Liping has reduced her holdings significantly, cashing out nearly 3 billion yuan, raising fears of further dilution of shares following the termination of the agreement [6]. Group 2: Operational Challenges - Kangtai Biological's core business includes the research, production, and sales of human vaccines, with key products such as the 13-valent pneumococcal polysaccharide conjugate vaccine and others [7]. - The company has faced significant operational challenges, including the resignation of a vice president and the termination of a joint venture with AstraZeneca, which was intended to invest approximately 2.76 billion yuan [8][10]. - The decision to terminate the joint venture was influenced by a rapidly changing market environment and increased risks associated with new investments in the vaccine industry [10]. Group 3: Financial Performance - Kangtai Biological's financial outlook is concerning, with a projected net profit for 2025 expected to decline by 63.80% to 75.70%, amounting to between 49 million and 73 million yuan [10]. - The company's performance has been volatile, with net profits peaking at 1.263 billion yuan in 2021, followed by a loss of 133 million yuan in 2022, and a recovery in 2023 and 2024, only to face another significant decline in 2025 [11]. - As of February 11, 2026, the company's stock price has plummeted nearly 90% from 146 yuan per share at the time of the divorce, reflecting a substantial decrease in valuation [11].

Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].